Giant Cell Arteritis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)
Giant cell arteritis (GCA) is an autoimmune disease marked by inflammation of blood vessels in the head and neck, especially the temporal arteries, leading to persistent headaches, flu-like symptoms, and the risk of blindness. High-dose corticosteroids form the cornerstone of GCA treatment; these drugs are typically initiated immediately after diagnosis to reduce the risk of blindness and tapered over the ensuing 12-24 months. In 2017, the FDA approved the first targeted treatment for GCA: Roche’s Actemra. Other key autoimmune drugs, including Bristol Myers Squibb’s Orencia, Eli Lilly’s Olumiant, AbbVie’s Rinvoq, and Sobi’s Kineret, are in late-phase trials for GCA, suggesting increasing interest in this potentially lucrative and untapped market.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed GCA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed GCA patients?
- How have DMARDs and Actemra been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of GCA patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
CONTENT HIGHLIGHTS
Markets covered: United States
Key companies: Bayer, Genentech / Roche, Novartis, Janssen, Bristol Myers Squibb
Key drugs: Actemra, corticosteroids, Cosentyx, methotrexate, aspirin, hydroxychloroquine, dapsone
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more-detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
Sheema Kher, M.Pharm., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Ms. Kher has much experience in the U.S. market access and payer landscape and has analyzed formulary and payer restrictions in multiple therapy areas for diverse lines of business, including commercial, HIX, managed Medicaid, state Medicaid, and Medicare. She holds a master’s degree in drug regulatory affairs from Amity University in Noida.